Not investment advice. This is a personal learning log. The authors are not SEBI-registered investment advisers or research analysts. Nothing here is a recommendation to buy or sell any security. Intraday levels are published only after the session has closed, as a record of what was tested. The portfolio is simulated, and past results don't predict future ones. Do your own research.

NSE Intraday Candidates — Wed 30 Sep 2026

Levels planned from Tue 29 Sep 2026 EOD only (not live)

1) Confirmation — data used

Session bar date: Tue 29 Sep 2026 (Yahoo Finance India .NS daily bars via scripts/eod_tech.py; Screener.in close prices match).
Index context: Nifty 50 closed 22,716.20 (−0.28% / −64.05 from Mon 22,780.25). Weak tape continues (third soft session after Fri's 23,140).
Technicals: Yahoo chart API; 20/50-DMA, RSI(14), vol vs 20d, RS vs Nifty from eod_tech.py (intraday/data/2026-09-30/eod_tech.json). No stale flags on finalists.
Fundamentals: Screener.in consolidated pages fetched 29 Sep 2026 evening IST.
Calendar: Wed 30 Sep 2026 is a normal NSE day. Fri 2 Oct 2026 is Gandhi Jayanti (closed) — next open after Thu 1 Oct is Mon 5 Oct.

Market bias for Wed: still risk-off / choppy. Prefer RS names with rising DMAs; cancel quickly if Nifty gaps hard lower.

Only 2 names clear quality (≥~15% ROE/ROCE, liquid enough for a ₹15k ticket, manageable debt) and Tue EOD momentum with a usable ~1% stop. Not forcing a third. Prior primary ZYDUSLIFE closed at the day low after hitting the target — not re-listed.

2) Ranked CANDIDATES

1) EMCURE (NSE) — PRIMARY

Fundamental (Screener.in, as of Tue 29 close ₹1,959):
ROE 20.1%, ROCE 24.0%; sales TTM +18%, profit TTM +37%; sales 3Y CAGR 15%, profit 3Y CAGR 21%; mcap ₹37,206 Cr; promoter ~77.8%. Borrowings ₹1,521 Cr vs equity ~₹4,950 Cr (D/E ≈ 0.31 — manageable). Screener flags rich P/B (~7.5×); no governance checklist red flag.

Technical setup (Tue 29 Sep EOD — Yahoo EMCURE.NS):
O 1,922.10 / H 1,987.10 / L 1,912.00 / C 1,959.10 (+1.62%); vol 3.31L vs ~20d avg ~1.99L (~1.67×). Above rising 20-DMA ~1,946 and rising 50-DMA ~1,926; RSI(14) ~53; 20d RS vs Nifty ~+11.7 pp; close_pos 0.63. Structure: bounce day with volume confirmation inside a choppy but rising DMA stack; recent swing high 2,101 (18 Sep), nearby supply 1,990–2,010.

Field	Level
Limit entry	1,959
Stop (~1%)	1,939
Target (realistic, fixed after gap)	1,995 – 2,010
R:R	~1.8 : 1 to ~2.5 : 1
Shares @ ₹150 risk	~7

Reason + source: Clean quality midcap pharma still above rising 20/50 with strong RS and above-average volume on a weak Nifty day; targets sit at the recent supply band with room so a small gap does not erase R:R. Yahoo EOD 29 Sep; Screener fundamentals.

Cancel at open: Gap open ≥1,979 (≥1% above entry); open ≤1,939; gap that pushes entry to/above target; or fails to hold 1,945 in the first 15–30 min with Nifty still selling.

2) LALPATHLAB (NSE) — SECONDARY

Fundamental (Screener.in, as of Tue 29 close ₹1,950):
ROE 22.3%, ROCE 28.0%; almost debt-free; sales TTM +14%, profit TTM +10%; mcap ₹32,746 Cr; promoter ~53%. Screener notes rich P/B (~13×) and modest 5Y sales growth (~12%). Results due 4 Nov 2026 (not a near-term event for Wed).

Technical setup (Tue 29 Sep EOD — Yahoo LALPATHLAB.NS):
O 1,943.60 / H 1,971.40 / L 1,930.60 / C 1,950.40 (+0.43%); vol 4.01L vs ~20d avg ~3.14L (~1.28× — just under the 1.3× preference). Above rising 20-DMA ~1,919 and rising 50-DMA ~1,900; RSI(14) ~59; 20d RS vs Nifty ~+8.0 pp; close_pos 0.49 (mid-range — weaker than primary). Structure: orderly hold above rising DMAs; nearby resistance 1,985–1,995 (25 Sep high zone), swing high 2,039 (16 Sep).

Field	Level
Limit entry	1,950
Stop (~1%)	1,931
Target (realistic, fixed after gap)	1,985 – 1,995
R:R	~1.8 : 1 to ~2.4 : 1
Shares @ ₹150 risk	~7

Reason + source: Quality diagnostics name with rising DMAs and positive RS; volume and close position are only average, so secondary. Yahoo EOD 29 Sep; Screener fundamentals.

Cancel at open: Gap open ≥1,970; open ≤1,931; or fails 1,935 early with Nifty still selling.

3) REJECTS (considered)

Name	Why rejected (1 line)
ZYDUSLIFE	Hit Tue target then closed at day low (close_pos 0) on 1.72× vol — distribution after the win; not re-chased.
DIVISLAB	Closed at day low; price_fit false (only 1 share).
LAURUSLABS	DMA/RS pass and last-year ROE 18% OK, but closed at day low (close_pos 0); 3Y ROE only ~10%.
SONACOMS	Tech pass (RS+, vol 2.2×) but Screener ROE 11.3% / ROCE 14.2% fail ≥15% quality.
AUROPHARMA	Above rising DMAs but Screener ROE/ROCE still fail quality (prior reject).
GLENMARK	Strong close/vol but 20-DMA not rising.
DRREDDY / MANKIND	Soft DMA slopes and/or ROE/ROCE under the gate.
APOLLOHOSP	Below both DMAs; 50-DMA not rising.
HINDZINC / OFSS / BSE / POLYCAB	Still below rising-DMA stack / weak RSI.
COALINDIA	Above 20/50 but 50-DMA not rising.

4) Desk paste (copy-paste ready)

Intraday desk — planned levels from Tue 29 Sep EOD for Wed 30 Sep session (not live)

Market: Nifty 22,716 (−0.28%). Weak tape; prefer RS. Fri 2 Oct Gandhi Jayanti closed.
If only one slot → EMCURE.

1) EMCURE — PRIMARY
Entry 1959 | Stop 1939 | Target 1995–2010 | R:R ~1.8–2.5 | ~7 sh @ ₹150 risk
ROE 20.1% ROCE 24% | Tue C 1959 H 1987 vol ~1.67x | above rising 20/50 RSI~53 RS+11.7
Cancel: gap ≥1979 or open ≤1939 or fails 1945 early

2) LALPATHLAB — SECONDARY
Entry 1950 | Stop 1931 | Target 1985–1995 | R:R ~1.8–2.4 | ~7 sh
ROE 22.3% ROCE 28% almost debt-free | Tue C 1950 close mid-range vol ~1.28x | rising 20/50 RSI~59 RS+8
Cancel: gap ≥1970 or open ≤1931 or fails 1935 early

No 3rd — ZYDUSLIFE day-low after target; LAURUSLABS day-low; SONACOMS ROE/ROCE; AUROPHARMA funda; most large caps still below rising DMAs.
Real Stock Trader sizes / proposes; the owner yes required. No live data.